As the pandemic continues, the rich are getting richer than ever before — and economists are getting concerned

“If the COVID-19 pandemic has produced winners and losers, then young Canadian billionaire Tobias Lütke is definitely a winner. Since the start of the pandemic in March, the 40-year-old CEO of Ottawa-based e-commerce company Shopify Inc., has watched his personal…

A Most Dangerous Intersection: Revisiting Race and Class in 2020

“In June, David Leonhardt in the New York Times noted that “the black-white wage gap is roughly as large today as it was in 1950.” One driver of this is that a huge number—a third of Black men ages 25-54—remain outside the…

US Pharma’s Financialized Business Model

By William Lazonick, Matt Hopkins, Ken Jacobson, Mustafa Erdem Sakinç and Öner Tulum ◊ Price gouging in the US pharmaceutical drug industry goes back more than three decades. In 1985 US Representative Henry Waxman, chair of the House Subcommittee on Health and the Environment, accused the pharmaceutical industry of “gouging the American public” with “outrageous” price increases, driven by “greed on a massive scale.” Even in the wake of the many Congressional inquiries that have taken place since the 1980s, including one inspired by the extortionate prices that Gilead Sciences has placed on its Hepatitis-C drugs Sovaldi since 2013 and Harvoni since 2014, the US government has not seen fit to regulate drug prices. UK Prescription Price Regulation Scheme data for 1996 through 2010 show that, while drug prices in other advanced nations were close to the UK’s regulated prices, those in the United States were between 74 percent and 181 percent higher.